The U.S. Food and Drug Administration (FDA) announced today the approval for the production and use of Choline C 11 Injection, a PET imaging agent used to help in the detection of prostate cancer.
Choline C 11 Injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer.
The Mayo Clinic is the first facility approved to manufacture Choline C 11 Injection. The agent is manufactured and distributed by the Mayo Clinic PET Radiochemistry Facility in Rochester, Minn.
To read the full FDA press release, visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm